Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | ALK negative |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ALK negative | lung non-small cell carcinoma | resistant | CEP-28122 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ALK negative non-small cell lung carcinoma cells were resistant to CEP-28122 in culture and in cell line xenograft models (PMID: 22203728). | 22203728 | |
ALK negative | leukemia | resistant | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative leukemia cells in culture (PMID: 22203728). | 22203728 | |
ALK negative | lymphoma | resistant | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative lymphoma cells in culture (PMID: 22203728). | 22203728 | |
ALK negative | colon carcinoma | resistant | CEP-28122 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CEP-28122 did not inhibit tumor growth in cell line xenograft models of ALK-negative colon carcinoma (PMID: 22203728). | 22203728 | |
ALK negative | anaplastic large cell lymphoma | predicted - sensitive | Brentuximab vedotin | Phase II | Actionable | In a Phase II trial (SGN-35), Adcetris (brentuximab vedotin) treatment resulted in complete remission in 57% (33/58), partial remission in 29% (17/58) of patients with relapsed or refractory systemic anaplastic large cell lymphoma, 72% (42/58) of the patients were ALK-negative (PMID: 22614995; NCT00866047). | 22614995 |